Omics-Based Clinical Trials Market Revenue to Attain USD 78.03 Bn by 2035
Published: 31 Dec 2025
Author: Precedence Research
Omics-Based Clinical Trials Market Revenue and Trends 2026 to 2035
The global omics-based clinical trials market revenue was valued at USD 35.71 billion in 2025 and is expected to attain around USD 78.03 billion by 2035, growing at a CAGR of 8.13% during forecast period. The market is expanding due to the increasing disease burden, chronic diseases, and shift towards personalized medicines for better results.
What are the Significant Driving Factors of the Omics-based Clinical Trials Market?
The market is expanding significantly due to advances in personalized medicine, which enable more precise and targeted therapies based on detailed analysis of genetic, proteomic, and molecular-level data. These approaches require extensive use of biochemical reagents across genomics, proteomics, and metabolomics workflows to support biomarker discovery, patient stratification, and therapy optimization.
In parallel, integration of AI and machine learning into omics-driven clinical trials is accelerating market growth by streamlining large-scale data processing and complex analytical tasks. AI-enabled platforms improve pattern recognition, predictive modeling, and data quality control across multi-omics datasets, reducing development timelines and improving trial efficiency.
These capabilities also support compliance with increasingly stringent safety and regulatory requirements by improving data traceability, reproducibility, and validation. As precision medicine programs and data-intensive clinical research continue to expand, demand for high-performance biochemical reagents is expected to remain strong across both research and clinical environments.
Segments Insights
- By omics type, the genomics segment held the largest market share in 2025. The segment is dominating as genomics directly links genetic makeup to disease and treatment, which is a foundational aspect of personalized medicine.
- By study phase, the phase II study segment held the largest market share in 2025. The segment is dominating, as the phase II study is critical to identify valid biomarkers and confirmation for drug efficiency in a larger group.
- By application, the oncology segment held the largest market share in 2025. The segment is dominating due to the increasing cases of cancers that stem from genetic mutations, which makes genomics a critical aspect to understand disease and curate personalized therapy for it.
- By end user, the pharmaceutical companies segment held the largest market share in 2025. The segment is dominating due to the massive funding and well-developed R&D infrastructure along with large-scale operations
- By service type, the omics data generation segment held the largest market share in 2025. The segment is dominating due to the holistic view of the biological system offered by omics data generation, facilitating faster drug discovery with the personalized medical treatment.
Regional Insights
North America held the largest market share in 2025, supported by its advanced healthcare infrastructure and the continuous launch of innovative medicines, diagnostics, and medical products by leading pharmaceutical and biotechnology companies. Strong adoption of genomics, molecular diagnostics, and precision medicine is reinforced by a well-defined regulatory framework under the U.S. Food and Drug Administration, which provides clear guidance for genomics-based research, clinical validation, and commercialization. High levels of public and private investment in life sciences R&D, combined with widespread use of advanced molecular technologies, continue to sustain the region’s leadership position.
Asia Pacific is projected to grow at the fastest CAGR during the foreseeable period, driven by rapid expansion of the biotechnology sector and rising clinical research activity. Countries such as China, India, and Japan are scaling investments in genomics infrastructure, biopharmaceutical manufacturing, and translational research programs. Increasing government support, growing numbers of clinical trials, and expanding academic and research institutions are collectively strengthening the region’s contribution to the market on a significant and sustained scale.
Omics-Based Clinical Trials Market Coverage
| Report Attribute | Key Statistics |
| Market Revenue in 2025 | USD 35.71 Billion |
| Market Revenue by 2035 | USD 78.03 Billion |
| CAGR from 2026 to 2035 | 8.13% |
| Quantitative Units | Revenue in USD million/billion, Volume in units |
| Largest Market | North America |
| Base Year | 2025 |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa |
Recent Development
- In January 2005, the leading pharma player, Parexel, introduced how new omics data along with deep learning models are effectively accelerating the findings of biomarkers for cancer development.(Source: https://www.parexel.com)
Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7259
You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344